Elnegouly M, Specht K, Zoller H, Matevossian E, Bassermann F, Umgelter A

Language: English
References: 34
Page: 592-597
PDF size: 224.61 Kb.

ABSTRACT

Hepatic involvement in AL amyloidosis may present as acute liver failure. Historically, liver transplantation in these cases has achieved poor outcomes due to progress of amyloidosis and non-hepatic organ damage. In the era of bortezomib treatment, the prognosis of AL amyloidosis has been markedly improved and may also result in better post-transplant outcomes. We present a case of isolated acute liver failure caused by AL amyloidosis, bridged to transplantation with bortezomib and treated with sequential orthotopic liver transplantation (OLT) and autologous stem cell transplantation. The patient is in stable remission 3 years after OLT.

REFERENCES

1. Kyle RA, Linos A, Beard CM, Linke RP, Gertz MA, O’Fallon WM, Kurland LT. Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood 1992; 79: 1817-22.

2. Gertz MA, Leung N, Lacy MQ, Dispenzieri A, Zeldenrust SR, Hayman SR, Buadi FK, et al. Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney. Nephrology, dialysis, transplantation 2009; 24: 3132-7.

3. Gertz MA, Kyle RA. Hepatic amyloidosis (primary [AL], immunoglobulin light chain): the natural history in 80 patients. Am JMedicine 1988; 85: 73-80.

4. Gullu BE, Hatemi I, Ozbay G, Tuzuner N, Sonsuz A. A rare case of primary systemic amyloidosis presenting with hepatic failure.The Turkish Journal of Gastroenterology 2011; 22: 113-4.

5. Nowak G, Westermark P, Wernerson A, Herlenius G, Sletten K, Ericzon BG. Liver transplantation as rescue treatment in a patient with primary AL kappa amyloidosis. Transplant Int 2000; 13: 92-7.

6. Sandberg-Gertzen H, Ericzon BG, Blomberg B. Primary amyloidosis with spontaneous splenic rupture, cholestasis, and liver failure treated with emergency liver transplantation. Am J Gastroenterol 1998; 93: 2254-6.

7. Lin TL, Wang PN, Kuo MC, Hung YH, Chang H, Tang TC. Cyclophosphamide plus granulocyte-colony stimulating factor for hematopoietic stem cell mobilization in patients with multiple myeloma. J Clin Apher 2015.

8. Yamamoto T, Maeda N, Kawasaki H. Hepatic failure in a case of multiple myeloma-associated amyloidosis (kappa-AL). J Gastroenterol 1995; 30: 393-7.

9. Levine RA. Amyloid disease of the liver. Correlation of clinical, functional and morphologic features in forty-seven patients. Am J Med 1962; 33: 349-57.

10. Kyle RA, Greipp PR. Amyloidosis (AL). Clinical and laboratory features in 229 cases. Mayo Clinic proceedings 1983; 58: 665-83.

11. Goenka MK, Bhasin DK, Vasisth RK, Dhawan S. Hepatic amyloidosis presenting with severe intrahepatic cholestasis. Journal Clin Gastroenterol 1996; 23: 134-6.

12. Rockey DC.Striking cholestatic liver disease: a distinct manifestation of advanced primary amyloidosis. Southern Medical Journal 1999; 92: 236-41.

13. Al-Saedi M. Liver Amyloidosis Complicated with Liver Failure: A Case Report and Review of the Literature. Journal of Gastrointestinal & Digestive System 2011; S3.

14. Ales NC, Daniels JT, Frizell ER, Koff JM, Kaplan KJ, Wortmann GW.Multiple myeloma-associated amyloidosis manifesting as fulminant hepatic failure. Southern Medical Journal 2001; 94: 1036-8.

15. Bataille R, Harousseau JL. Multiple myeloma. N Engl J Med 1997; 336: 1657-64.

16. Jaccard A, Comenzo RL, Hari P, Hawkins PN, Roussel M, Morel P, Macro M, et al. Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naive patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III). Haematologica 2014; 99: 1479-85.

17. Merlini G, Stone MJ: Dangerous small B-cell clones. Blood 2006; 108: 2520-30.

18. Jones NF, Tighe JR, Hilton PJ, Hobbs JR. Treatment of Primary Renal Amyloidosis with Melphalan. Lancet 1972; 2: 616-&.

19. Leung N, Glavey SV, Kumar S, Dispenzieri A, Buadi FK, Dingli D, Lacy MQ, et al. A detailed evaluation of the current renal response criteria in AL amyloidosis: is it time for a revision? Haematologica 2013; 98: 988-92.

20. Comenzo RL, Vosburgh E, Falk RH, Sanchorawala V, Reisinger J, Dubrey S, Dember LM, et al. Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients. Blood 1998; 91: 3662-70.

21. Girnius S, Seldin DC, Skinner M, Finn KT, Quillen K, Doros G, Sanchorawala V. Hepatic response after high-dose melphalan and stem cell transplantation in patients with AL amyloidosis associated liver disease. Haematologica 2009; 94: 1029-32.

22. Dispenzieri A, Merlini G, Comenzo RL. Amyloidosis: 2008 BMT Tandem Meetings (February 13-17, San Diego). Biology of blood and marrow transplantation 2008; 14: 6-11.

23. Dispenzieri A, Lacy MQ, Rajkumar SV, Geyer SM, Witzig TE, Fonseca R, Lust JA, et al. Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis. Amyloid 2003; 10: 257-61.

24. Sanchorawala V, Wright DG, Rosenzweig M, Finn KT, Fennessey S, Zeldis JB, Skinner M, et al. Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. Blood 2007; 109: 492-6.

25. Moreau P, Jaccard A, Benboubker L, Royer B, Leleu X, Bridoux F, Salles G, et al. Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study. Blood 2010; 116: 4777-82.

26. Specter R, Sanchorawala V, Seldin DC, Shelton A, Fennessey S, Finn KT, Zeldis JB, et al. Kidney dysfunction during lenalidomide treatment for AL amyloidosis. Nephrology, dialysis, transplantation 2011; 26: 881-6.

27. Wechalekar AD, Lachmann HJ, Offer M, Hawkins PN, Gillmore JD. Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease. Haematologica 2008; 93: 295-8.

28. Lamm W, Willenbacher W, Lang A, Zojer N, Muldur E, Ludwig H, Schauer-Stalzer B, et al. Efficacy of the combination of bortezomib and dexamethasone in systemic AL amyloidosis. Ann Hematology 2011; 90: 201-6.

29. Kastritis E, Wechalekar AD, Dimopoulos MA, Merlini G, Hawkins PN, Perfetti V, Gillmore JD, et al. Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. J Clin Oncol 2010; 28: 1031-7.

30. San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, et al: Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalanprednisone in patients with previously untreated multiple myeloma. J Clin Oncol 2013; 31: 448-55.

31. Engelhardt M, Terpos E, Kleber M, Gay F, Wasch R, Morgan G, Cavo M, et al. European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. Haematologica 2014; 99: 232-42.

32. Parikh R, Tsai CS. Amyloidosis presenting as acute liver failure: a case report. Internal Medicine Inside 2014; 2: 5.

33. Cross TJ, Wendon JA, Quaglia A, Salisbury JR, Heneghan MA, Harrison PM. Myeloma associated amyloidosis presenting as subacute liver failure. Postgraduate Medical Journal 2006; 82: e13.

34. Sattianayagam PT, Gibbs SD, Pinney JH, Wechalekar AD, Lachmann HJ, Whelan CJ, Gilbertson JA, et al. Solid organ transplantation in AL amyloidosis. Am J Transplant 2010; 10: 2124-31.